Gore announces transition of commercial support for the GORE^® VIABIL^® Biliary Endoprosthesis in the United States

FLAGSTAFF, Ariz. (December 5, 2025) – W. L. Gore & Associates’ (Gore) medical products business, along with Olympus Corporation (“Olympus”) and ConMed Corporation (“ConMed”), jointly announced the upcoming transition of commercial support and distribution for the GORE^® VIABIL^® Biliary Endoprosthesis for endoscopic placement ("VIABIL^® Device") in the United States.

This announcement follows Gore’s selection of Olympus as the exclusive international distributor of the VIABIL^® Device. Effective January 1, 2026, the distribution of the VIABIL^® Device in the United States will also transition to Olympus. Olympus representatives will become the primary contact for all orders as of that date. ConMed will continue to fully support the product until December 31, 2025.

Gore, Olympus, and ConMed are committed to a smooth and coordinated transition of distribution services, ensuring continuity of service and access for health care providers and patients.